The inhibition of MAPK pathway is correlated with down-regulation of MMP-9 secretion induced by TNF-α in human keratinocytes

被引:65
作者
Holvoet, S [1 ]
Vincent, C [1 ]
Schmitt, D [1 ]
Serres, M [1 ]
机构
[1] Hop Edouard Herriot, INSERM, U346, Lab Peau Humaine & Immunite, F-69437 Lyon 03, France
关键词
HaCaT cells; human keratinocytes; metalloproteinases; MAPK; NF-kappa B; transduction signal pathways;
D O I
10.1016/S0014-4827(03)00293-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MMP-9 (92 kDa) is the major gelatinase able to degrade collagen IV, secreted by keratinocytes that are actively involved in wound-healing or tumorigenesis. Since the invasive phenotype of cancers is dependent on MMP-9 expression, it appeared of interest to precisely characterize which signal transduction pathways activated by TNF-alpha are involved in MMP-9 up-regulation induced by TNF-a. In HaCaT cells, activation of MMP-9 occurs at the transcriptional level. Inhibition of the MAPK pathway using specific inhibitors of the Ras, Raf, MEK1/2, and Erk1/2 cascade was correlated with a marked inhibition of MMP-9 activity, as determined by gene and protein expression. MAPK pathway activation via TNF-alpha was confirmed by marked AP-1 activation detected in EMSA. Under our experimental conditions, p38 MAPK and SAPK/JNK pathways were not activated. Gene and protein expression of other MMPs that regulate MMP-9, such as MMP-1 and MMP-13, were also up-regulated by TNF-alpha and inhibited by UO126, providing evidence that the MAPK pathway plays a fundamental role in the regulation of MMP-9 secretion by keratinocytes. As TNF-alpha is known to be a main activator of NF-kappaB pathway, the effects of campthothecin and caffeic acid were investigated, such as, TNF-alpha campthothecin up-regulated MMP-9 activity but caffeic acid only weakly inhibited MMP-9 activation induced by TNF-alpha. However, NF-kappaB is activated as shown from immunostaining data, a nuclear staining and higher Western blotting expression of p50 and p65 NF-kappaB subunits were detected, after TNF-alpha treatment. A higher specific signal was also detected in EMSA for TNF-alpha-treated cells. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:108 / 119
页数:12
相关论文
共 79 条
[1]   Differential stromal regulation of MMP-1 expression in benign and malignant keratinocytes [J].
Airola, K ;
Fusenig, NE .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 116 (01) :85-92
[2]   Matrix metalloproteinases-2,-3,-7,-9 and-10, but not MMP-11, are differentially expressed in normal, benign tumorigenic and malignant human keratinocyte cell lines [J].
Bachmeier, BE ;
Boukamp, P ;
Lichtinghagen, R ;
Fusenig, NE ;
Fink, E .
BIOLOGICAL CHEMISTRY, 2000, 381 (5-6) :497-507
[3]  
Bachmeier BE, 2002, INT J ONCOL, V20, P495
[4]   Human keratinocyte cell lines differ in the expression of the collagenolytic matrix metalloproteinases-1,-8, and-13 and of TIMP-1 [J].
Bachmeier, BE ;
Nerlich, AG ;
Boukamp, P ;
Lichtinghagen, R ;
Tschesche, H ;
Fritz, H ;
Fink, E .
BIOLOGICAL CHEMISTRY, 2000, 381 (5-6) :509-516
[5]  
BAUMAN P, 1999, ARCH DERMATOL RES, V291, P128
[6]   Cytotoxic signal transmission pathways via TNF family receptors [J].
Beletsky, IP ;
Moshnikova, AB ;
Prusakova, OV .
BIOCHEMISTRY-MOSCOW, 2002, 67 (03) :312-328
[7]   NORMAL KERATINIZATION IN A SPONTANEOUSLY IMMORTALIZED ANEUPLOID HUMAN KERATINOCYTE CELL-LINE [J].
BOUKAMP, P ;
PETRUSSEVSKA, RT ;
BREITKREUTZ, D ;
HORNUNG, J ;
MARKHAM, A ;
FUSENIG, NE .
JOURNAL OF CELL BIOLOGY, 1988, 106 (03) :761-771
[8]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[9]   Tissue inhibitors of metalloproteinases: evolution, structure and function [J].
Brew, K ;
Dinakarpandian, D ;
Nagase, H .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1477 (1-2) :267-283
[10]   Matrix-metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions:: an in situ hybridization study [J].
Brummer, O ;
Athar, S ;
Riethdorf, L ;
Löning, T ;
Herbst, H .
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1999, 435 (06) :566-573